Dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid, likely triggered by scabies, in a hemodialysis patient with human leukocyte antigen-DQB1*03:01
Authors:
- 28 January 2020
- journal article
- case report
- Published by Springer Nature in CEN Case Reports
- Vol. 9 (3) , 189-194
Abstract
Bullous pemphigoid (BP) is the most common autoimmune subepidermal bullous diseases. Autoantibodies against hemidesmosomal adhesion proteins might be involved in the developing process. BP usually affects the elderly with high mortality whereas the drug-induced BP is often improved and rarely relapses after the withdrawal of the suspected drug. An accumulated evidence suggests that dipeptidyl peptidase-4 inhibitor (DPP-4I), which has been widely used as the antidiabetic drug improves glycemic control with little risk for hypoglycemia, could be an inducer of DPP-4I-associated BP (DPP-4I-BP). While the precise mechanism remains unclear, a unique immunological profile with human leukocyte antigen (HLA)-DQB1*03:01 could be a biomarker of genetic susceptibility to DPP-4I-BP. Here, we encountered an interesting case of DPP-4I-BP with HLA-DQB1*03:01, which was likely triggered by scabies. A 56-year-old Japanese male with type 2 diabetes on hemodialysis was referred to our hospital due to worsened blisters. Prior to his admission, he had been on linagliptin, a DPP-4I, for 5 months. He then suffered from scabies 2 weeks before his admission while the treatment with ivermectin failed to improve his symptom. Based on his clinical symptom, positive for anti-BP180 autoantibody in serum, and the pathological alterations of skin biopsy specimens, he was diagnosed with DPP-4I-BP. Importantly, he also carried an HLA-DQB1*03:01 allele. Oral prednisolone was subsequently administered after the discontinuation of linagliptin, and his symptom gradually disappeared. Given the fact that the DPP-4I-BP could be a life-threating disease, we should be cautious of prescribing DPP-4I in hemodialysis patients, whose immune system could be impaired.Keywords
This publication has 37 references indexed in Scilit:
- Drug‐induced pemphigoid: a review of the literatureJournal of the European Academy of Dermatology and Venereology, 2014
- Cutaneous Manifestations of ESRDClinical Journal of the American Society of Nephrology, 2014
- Increased risk of pemphigoid following scabies: a population‐based matched‐cohort studyJournal of the European Academy of Dermatology and Venereology, 2013
- Drug‐induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase‐IV inhibitors plus metforminJournal of the European Academy of Dermatology and Venereology, 2011
- Dipeptidyl Peptidase IV Inhibitors and the Incretin System in Type 2 Diabetes MellitusPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2007
- Elevated expression of CD23 on peripheral blood B lymphocytes from patients with bullous pemphigoid: correlation with increased serum IgEJournal of Dermatological Science, 2004
- Serum Levels of Soluble CD23 in Patients with Bullous PemphigoidThe Journal of Dermatology, 1995
- Soluble CD23 as an effector of immune dysregulation in chronic uremia and dialysisKidney International, 1993
- Pseudouremic Pruritus: A Scabies Epidemic in a Dialysis UnitAmerican Journal of Kidney Diseases, 1985
- Increased frequency of diabetes mellitus in patients with bullous pemphigoid: A case-control studyJournal of the American Academy of Dermatology, 1984